Table 3 The details of pooled 6-month PFS rate and 12-month OS rate
| Â | Subgroups | Pooled rate (95% CI), % | No. of cohorts | I2 (95% CI), % | P for I2 | Model | Egger's Test |
|---|---|---|---|---|---|---|---|
6-month PFS rate | ICIs based-therapy | 32.8 (23.5–42.7) | 20 | 79.4 (68.8- 86.4) |  < 0.01 | Random effect | z = -0.1, p-value = 0.95 |
anti-PD-(L)1 + chemotherapy | 23.1 (9.6–39.7) | 2 | 0.0 | 0.99 | Fixed effect | / | |
anti-PD-(L)1 + TKIs | 29.3 (17.0–43.2) | 10 | 80.5 (65.1- 89.1) |  < 0.01 | Random effect | z = -1.1, p-value = 0.28 | |
anti-PD-(L)1 + anti-VEGF + chemotherapy | 55.2 (24.8–83.8) | 3 | 80.7 (39.4- 93.8) |  < 0.01 | Random effect | z = 0.5, p-value = 0.60 | |
anti-PD-(L)1 + anti-EGFR + chemotherapy | 39.1 (19.3–60.7) | 2 | 0.0 | 0.94 | Fixed effect | / | |
First-line | 71.5 (53.5–86.8) | 2 | 0.0 | 0.37 | Fixed effect | / | |
Second-line or beyond | 30.4 (21.5–40.0) | 17 | 77.0 (63.5–85.5) |  < 0.01 | Random effect | z = -0.5, p-value = 0.62 | |
12-month OS rate | ICIs based-therapy | 52.3 (46.4–58.1) | 12 | 36.0 (0.0- 67.7) | 0.10 | Fixed effect | z = -0.1, p-value = 0.89 |
anti-PD-(L)1 + TKIs | 52.1 (42.9–61.3) | 5 | 0.0 (0.0- 76.2) | 0.48 | Fixed effect | z = 0.3, p-value = 0.80 | |
anti-PD-(L)1 + anti-VEGF + chemotherapy | 71.4 (50.0–89.1) | 1 | / | / | / | / | |
anti-PD-(L)1 + anti-EGFR + chemotherapy | 47.8 (26.9–69.1) | 2 | 0.0 | 0.86 | Fixed effect | / | |
First-line | 71.4 (50.0–89.1) | 1 | / | / | / | / | |
Second-line or beyond | 51.2 (45.1–57.3) | 10 | 33.0 (0.0–68.1) | 0.14 | Fixed effect | z = 0.0, p-value = 1.00 |